Who Should Be Tested?

57% heritability for all PCa, including sporadic, highest in all cancers

Rare pathogenic mutations (RPM)

Common risk-associated SNPs (GRS)

Most prostate cancer patients and their families can benefit from germline testing.

NCCN Guideline Recommendations

Who Should Be Tested?

Family history of hereditary cancer syndromes and/or high-risk germline mutations (e.g. BRCA1/2, Lynch gene mutation)

Family history of other potential high-risk germline mutations (e.g. ATM, CHEK2, PALB2, HOXB13)

Patients with a high to very high risk and/or regional or metastatic disease

Patients with high-risk family history, intraductal histologies or other conditions, regardless of risk

High-risk family history includes:

A first-degree relative or multiple relatives <60y who were diagnosed or died of prostate cancer

Ashkenazi Jewish ancestry

≥3 cases of any cancer on the same side of the family

Other conditions include:

Men with a family history of hereditary cancer syndromes (HBOC, Lynch or others)

FOR UNAFFECTED MEN

Men with a family history of pathogenic mutations with cancer syndromes